CHERYL MURO: Open Payments
NPI 1720400252 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$936 in 10 payments from 9 companies in 2025. Trend: 2023 $416 · 2024 $414 · 2025 $936
Food & beverage: $936
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 1 | $130 |
| GlaxoSmithKline, LLC. | 1 | $120 |
| Sumitomo Pharma America, Inc. | 1 | $119 |
| Axsome Therapeutics, Inc. | 1 | $119 |
| Kowa Pharmaceuticals America, Inc. | 1 | $117 |
| Merck Sharp & Dohme LLC | 1 | $114 |
| ABBVIE INC. | 1 | $100 |
| PFIZER INC. | 1 | $81 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $36 |
Products named: REPATHA, AREXVY, GEMTESA, Symbravo, ZORYVE, CAPVAXIVE, QULIPTA, NURTEC ODT.
Industry payments across MO — which companies pay providers there.
